Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by HC Wainwright to Strong-Buy Rating

HC Wainwright upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) to a strong-buy rating in a research note released on Thursday,Zacks.com reports.

Other research analysts also recently issued reports about the stock. Royal Bank Of Canada boosted their price objective on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, August 14th. Evercore reaffirmed an “outperform” rating and issued a $329.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $333.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, August 13th. Barclays decreased their price target on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Finally, TD Cowen raised their price objective on shares of Ascendis Pharma A/S from $325.00 to $341.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $302.68.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $249.36 on Thursday. The company has a market capitalization of $15.56 billion, a P/E ratio of 19.35 and a beta of 0.39. Ascendis Pharma A/S has a fifty-two week low of $186.05 and a fifty-two week high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The stock has a 50 day moving average price of $255.40 and a two-hundred day moving average price of $239.02.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The firm had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Analysts expect that Ascendis Pharma A/S will post 3.9 earnings per share for the current year.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 2,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were acquired at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the acquisition, the director owned 2,900 shares in the company, valued at $714,357. This trade represents a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 40.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the stock. Advisory Services Network LLC purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at about $26,000. Arax Advisory Partners raised its holdings in Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after buying an additional 104 shares during the last quarter. Leonteq Securities AG bought a new position in shares of Ascendis Pharma A/S in the fourth quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Ascendis Pharma A/S in the fourth quarter worth approximately $42,000. Finally, Global Retirement Partners LLC grew its holdings in shares of Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 113 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.